12 Month Price Forecast For NVNO
Distance to NVNO Price Forecasts
NVNO Price Momentum
🤔 Considering enVVeno Medical (NVNO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 22, 2025 8:17 PM UTC
NVNO Analyst Ratings & Price Targets
Based on our analysis of 0 Wall Street analysts, NVNO has a consensus that is bullish. The median price target is $18.00, with forecasts ranging from $18.00 to $18.00. Currently, there are 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With NVNO currently trading at $3.49, the median price forecast suggests a 415.8% upside. The most optimistic forecast comes from at , projecting a 415.8% upside, while at provides the most conservative target, suggesting a 415.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVNO Analyst Consensus
NVNO Price Target Range
Latest NVNO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVNO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Stocks Similar to enVVeno Medical Corporation
The following stocks are similar to enVVeno Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
enVVeno Medical Corporation (NVNO) Financial Data
enVVeno Medical Corporation has a market capitalization of $57.52M with a P/E ratio of -1.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -58.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
enVVeno Medical Corporation (NVNO) Company Overview
About enVVeno Medical Corporation
Develops bioprosthetic solutions for venous diseases.
The company operates as a clinical-stage medical device firm, focusing on innovative treatments for venous diseases. Its primary revenue potential lies in the commercialization of its lead product, the VenoValve, and the transcatheter enVVe valve, both targeting Chronic Venous Insufficiency (CVI).
Founded in 1999 and based in Irvine, California, enVVeno Medical Corporation was previously known as Hancock Jaffe Laboratories, Inc. The company is committed to enhancing patient outcomes in venous disease treatment through its advanced bioprosthetic technologies.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
31
CEO
Mr. Robert A. Berman
Country
United States
IPO Year
1999
Website
www.envveno.comenVVeno Medical Corporation (NVNO) Latest News & Analysis
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
1 month agoenVVeno Medical Corporation completed all planned implants in its GLP study for the enVVe delivery system, confirming consistent performance. IDE application submission is on track for mid-2025.
Successful completion of the GLP study enhances enVVeno's credibility and paves the way for the upcoming IDE application, potentially accelerating market entry and impacting stock performance.
enVVeno Medical Corporation (NASDAQ: NVNO) launched a recap website for its participation in the 51st VEITH Symposium, showcasing data from the VenoValve® U.S. Pivotal Trial.
The launch of a recap website and participation in a major symposium signals enVVeno Medical's commitment to transparency and innovation, potentially boosting investor confidence and interest.
The FDA has approved VenoValve's PMA, which could enhance NVNO's bioprosthetic product offerings.
FDA approval of VenoValve's PMA could enhance NVNO's market position and revenue streams, positively impacting stock performance and investor confidence.
enVVeno Medical Corporation (NASDAQ: NVNO) will present definitive one-year data from its PMA application for the VenoValve at the VEITH Symposium on November 20. Four of five modules are FDA approved.
The submission of the VenoValve PMA application and upcoming data presentation could signal FDA approval, potentially boosting enVVeno's stock and market position in venous disease treatment.
enVVeno Medical Corporation (NASDAQ: NVNO) reports strong one-year data from the VenoValve trial, showing 85% responder rate, 75% pain reduction, and 97% vein patency. PMA submitted to FDA.
Positive clinical trial results and FDA pre-market authorization could lead to increased sales and market share for enVVeno Medical, impacting stock performance and investor sentiment.
Frequently Asked Questions About NVNO Stock
What is enVVeno Medical Corporation's (NVNO) stock forecast for 2025?
Based on our analysis of 0 Wall Street analysts, enVVeno Medical Corporation (NVNO) has a median price target of $18.00. The highest price target is $18.00 and the lowest is $18.00.
Is NVNO stock a good investment in 2025?
According to current analyst ratings, NVNO has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.49. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for NVNO stock?
Wall Street analysts predict NVNO stock could reach $18.00 in the next 12 months. This represents a 415.8% increase from the current price of $3.49. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is enVVeno Medical Corporation's business model?
The company operates as a clinical-stage medical device firm, focusing on innovative treatments for venous diseases. Its primary revenue potential lies in the commercialization of its lead product, the VenoValve, and the transcatheter enVVe valve, both targeting Chronic Venous Insufficiency (CVI).
What is the highest forecasted price for NVNO enVVeno Medical Corporation?
The highest price target for NVNO is $18.00 from at , which represents a 415.8% increase from the current price of $3.49.
What is the lowest forecasted price for NVNO enVVeno Medical Corporation?
The lowest price target for NVNO is $18.00 from at , which represents a 415.8% increase from the current price of $3.49.
What is the overall NVNO consensus from analysts for enVVeno Medical Corporation?
The overall analyst consensus for NVNO is bullish. Out of 0 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $18.00.
How accurate are NVNO stock price projections?
Stock price projections, including those for enVVeno Medical Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
